- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
As a broad-spectrum antibiotic, ciprofloxacin is used to treat a variety of bacterial infections, including uncomplicated and serious urinary tract infections (UTIs), where other antibiotics are ineffective. infections of the skin, bones, and chest (including pneumonia).
A number of different bacterial infections are treated with this medicine. Ciprofloxacin is a member of the quinolone antibiotics medication class.
It acts by preventing bacterial development.Only bacterial illnesses are treated by this antibiotic. For viral infections, it is ineffective. (such as the common cold, flu). Any antibiotic that is overused may stop working to treat subsequent illnesses.
Fluoroquinolone (flor-o-KWIN-o-lone) antibiotic ciprofloxacin is used to treat several bacterial illnesses. People who have been exposed to anthrax or specific types of plague are also treated with it. The use of ciprofloxacin extended-release is only permitted in adults.
Serious adverse effects of ciprofloxacin might include tendon issues, nerve damage, significant changes in mood or behaviour, and low blood sugar.
Bacterial infections can occur in many different places of the body, and ciprofloxacin is used to treat them. Infection from anthrax following inhalation exposure is also treated with ciprofloxacin oral liquid and tablets. Additionally, this medication is used to treat and prevent plague.
(including pneumonic and septicemic plague). The effects of ciprofloxacin may conceal or postpone syphilis symptoms. Syphilis infections are not successfully treated.
The only condition for which ciprofloxacin extended-release tablets are prescribed is urinary tract infections, including acute simple pyelonephritis.
Only basic or uncomplicated urinary tract infections are treated with Proquin XR pills. (acute cystitis).Ciprofloxacin is a member of the quinolone antibiotics medication class.
It functions by eradicating bacteria or stopping their growth. However, this medication won't help with the flu, the common cold, or other viral infections.
The Global CiprofloxacinMarket accountedfor $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The fluoroquinolone antibiotic ciprofloxacin is used to treat bacterial illnesses like pneumonia and urinary tract infections.
The FDA has given ciprofloxacin permission to treat salmonellosis, anthrax, plague, gonorrhoea, skin, bone, and joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, and sexually transmitted infections (gonorrhoea and chancroid).
Additionally, individuals with mixed infections or those who have risk factors for Gram-negative infections should consider ciprofloxacin as a therapy option.
Members of the interprofessional team should study the indications, coverage, contraindications, and adverse event profile of the broad-spectrum quinolone antibiotic ciprofloxacin in order to manage infectious illnesses in patients as effectively as possible.
A fluoroquinolone antibiotic called ciprofloxacin is used to treat a variety of bacterial illnesses.This includes, among others, infections of the bones and joints, the abdomen, specific forms of infectious diarrhoea, the respiratory and skin tracts, typhoid fever, and urinary tract infections.
It is used in conjunction with other antibiotics for some illnesses.It can be administered intravenously, as eye drops, ear drops, or by mouth.
Infections of the bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid are just a few of the infections that can be treated with ciprofloxacin.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Admin Pvt Ltd. All rights reserved.